about
Rarity of the Alzheimer disease-protective APP A673T variant in the United StatesEffect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx studyThe effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patientsCommon variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association studyWhite matter tract integrity metrics reflect the vulnerability of late-myelinating tracts in Alzheimer's disease.The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers.Age-related non-Gaussian diffusion patterns in the prefrontal brain.The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study.Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severityThe cognitive syndrome of vascular dementia: implications for clinical trials.Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.Vitamin E and donepezil for the treatment of mild cognitive impairment.Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).Barriers to drug discovery and development for Alzheimer disease.Clinical trials in AD: are current formats and outcome measures adequate?Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline.GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90Mild cognitive impairment: historical development and summary of researchTracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function InstrumentAlzheimer's disease. Diagnosis by specialists: psychological testing.Differential diagnosis and clinical assessment of patients with severe Alzheimer disease.Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice.ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.Evaluation of memantine for the treatment of Alzheimer's disease.Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease developmentNeuropsychological and neuropsychiatric prediction of global cognitive status among older Spanish-speaking Hispanics and English-speaking whites.Novel late-onset Alzheimer disease loci variants associate with brain gene expression.Pilot study to show the feasibility of a multicenter trial of home-based assessment of people over 75 years old.A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline.
P50
Q27346292-24452609-1264-476E-80C7-9CDC1A23CF50Q28302829-AF17DA19-44F8-47DF-8D0F-0F8DCA064BBBQ28340611-CCEDB1E8-CE50-4F10-B238-5B2F9061B0A0Q28943325-55289B1E-4F65-4F6E-ABB4-0A1E794217B2Q30459046-9521DEFA-BCFF-4850-9178-DD80F155C7A7Q30711356-659E8196-8FF9-4BA3-BE07-0D9ED4A513CCQ31081008-B5181394-610B-4EC3-85BC-4A2AFF69C140Q33386359-A50983B0-B474-49BF-81B6-2E94C513A4BEQ33454243-8D3DFCEB-FE77-4378-A422-B3D4F9CFC2A9Q33623399-1651C1F2-15CE-48DE-8253-832EA50A5C58Q33675522-DBF9A9F7-50C8-4F51-84F8-95AA0A9BF09FQ33746082-36ECF299-7FFA-4D33-89FA-E63053AA528CQ33803117-63539570-3DBF-4A45-910E-88B338D12F58Q33968308-706865E7-9BDF-486E-8B63-3E599DDCC174Q34157492-E308125B-FCC2-4C7F-B672-49601C74F530Q34411313-002BC0A2-F822-4E21-AB87-BD2131E55249Q34433710-E3264DAB-AFE0-4E98-BD6F-5D9D57E64D58Q34433716-094161F7-FDDC-480F-9736-0C5AF7D34F77Q34433720-7FCE8879-09D4-4F07-8D64-F798646CB730Q34635541-EE203A78-65A7-4264-94CD-5DB6DB8A83D9Q34691815-86773F54-5722-40DF-9834-AF8AE567AE1DQ34691827-B4F056CC-19D0-4CF9-8E20-FBE252C783F0Q34984743-BF57385B-6B6A-4BBC-94DF-97EDE03C4C1AQ34987567-EA0527CE-9B3F-4564-A90A-5360BB21D224Q35015551-B474448D-EF58-42B2-82EF-9D903D7314E1Q35103887-DCAF6F87-1033-40D9-9B2D-7543FB26619EQ35236843-533604D6-4877-4A05-9D81-BB069EC23BB8Q35418054-E6BB05C2-1992-4D9E-9EAF-C3908F20C24EQ35436010-177DB809-CE0C-44DD-BF4E-8508FD91E96FQ35544980-527C1017-FB6A-4D0B-92F6-63CBFD7263D3Q35557603-5750A971-A03B-437F-AF41-AA6C9811F415Q35588243-A77A2E9D-7DFE-4F3C-A1BC-2BA3BC1FBCEBQ35594009-4409E5B7-88D4-4F07-B87A-F4B0F4F2FAC5Q35651618-0D10A3E8-A30E-4EE7-AB31-9AFA71ABE513Q35735243-A9749D84-316A-4E29-B3BB-954F1D1AC269Q36099525-FF97BF03-6F80-4864-A9E7-765F62FB7E2AQ36478318-615268F3-6C85-48C2-9408-8D708837EB6EQ36893856-826B636B-6038-492D-A0EC-13C37EA35126Q37084847-B393F823-2121-43DE-8F0B-7C065DDC5242Q37141212-ED6933C9-F861-4AFC-B318-AC24CC3479E8
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Steven H Ferris
@ast
Steven H Ferris
@en
Steven H Ferris
@es
Steven H Ferris
@nl
Steven H Ferris
@sl
type
label
Steven H Ferris
@ast
Steven H Ferris
@en
Steven H Ferris
@es
Steven H Ferris
@nl
Steven H Ferris
@sl
altLabel
Steven Ferris
@en
prefLabel
Steven H Ferris
@ast
Steven H Ferris
@en
Steven H Ferris
@es
Steven H Ferris
@nl
Steven H Ferris
@sl
P106
P21
P31
P496
0000-0001-8641-6223